Physician profile
Scott D Becker
NPI 1912982596
$30,950.19
in general payments reported to CMS, 2019-2025
41 companies · $8,102 in 2025
The $8,102 reported for 2025 was more than what 92% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,416 · 2020: $953 · 2021: $1,934 · 2022: $1,625 · 2023: $2,377 · 2024: $8,543 · 2025: $8,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,815 · Food and Beverage: $8,401 · Travel and Lodging: $1,788 · Education: $17.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,815.00 |
| Food and Beverage | $8,400.92 |
| Travel and Lodging | $1,788.00 |
| Education | $17.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $11,150.42 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $6,952.83 | 2019-2025 | |
| Abbvie INC. | $4,525.76 | 2019-2025 | Rinvoq, Skyrizi, Viberzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,362.71 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Celgene Corporation | $1,206.27 | 2021-2024 | Zeposia |
| Pfizer INC. | $855.39 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $695.08 | 2019-2025 | Tremfya, Stelara, Remicade |
| Janssen Biotech, INC. | $583.47 | 2019-2025 | Tremfya, Stelara |
| Genzyme Corporation | $450.57 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $337.03 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Nestle Healthcare Nutrition INC. | $313.17 | 2021-2023 | |
| Redhill Biopharma INC. | $233.56 | 2021-2023 | Talicia, Movantik, Aemcolo |
| Madrigal Pharmaceuticals | $203.71 | 2024-2025 | Resmetirom, Rezdiffra |
| Aimmune Therapeutics, INC. | $195.39 | 2023-2025 | Zenpep, Vowst |
| Celltrion USA INC. | $193.13 | 2024-2025 | Vegzelma, Zymfentra |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $190.70 | 2025 | Sucraid |
| Ipsen Biopharmaceuticals, INC | $184.66 | 2024-2025 | Iqirvo, Bylvay |
| Lilly USA, LLC | $169.75 | 2023-2025 | Omvoh |
| Ardelyx, INC. | $158.92 | 2023-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $150.86 | 2020-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $146.07 | 2023-2024 | Dificid |
| Daiichi Sankyo INC. | $145.84 | 2020-2023 | Injectafer |
| Biogen, INC. | $84.91 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $71.47 | 2025 | Dupixent |
| Boston Scientific Corporation | $52.48 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $45.42 | 2019-2021 | |
| Braintree Laboratories, INC. | $39.94 | 2020-2024 | Sutab, Suflave |
| Ferring Pharmaceuticals INC. | $35.22 | 2023-2024 | Rebyota |
| Baxter Healthcare | $32.92 | 2020 | |
| Olympus America INC. | $32.65 | 2023-2025 | Evis Exera III Colonovideoscope, Evis Exera Lll Colonovideoscope, Evis Exera III Duodenovideoscope |
| Fresenius Kabi USA, LLC | $23.68 | 2023 | Idacio |
| Mauna Kea Technologies, INC. | $21.98 | 2025 | |
| Allergan, INC. | $18.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.97 | 2022 | |
| Novo Nordisk INC | $13.83 | 2025 | Wegovy |
| Enterra Medical, INC. | $13.55 | 2025 | |
| Dova Pharmaceuticals | $13.38 | 2019 | |
| Alnylam Pharmaceuticals INC. | $13.10 | 2020 | |
| Endo Pharmaceuticals INC. | $12.62 | 2020 | |
| Endogastric Solutions, INC | $4.13 | 2023 | Esophyx |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$32,796.47 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.